Results 131 to 140 of about 57,284 (206)

Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Muhammad Daniyal S, Ajaz H, Riaz M, Murad Khatoon N, Aftab Z, Tauqir Gondal H, Gul I, Sarwar M, Batool F, Fahim SL, Noor A, Khalid A, Ashraf DA, Jabarkhil R.   +13 more
europepmc   +1 more source

Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia. [PDF]

Am Heart J Plus
Hassen M, Worku BT, Solomon T, Demessie MB, Wendie TF, Muhammed OS, Gobezie MY.   +6 more
europepmc   +1 more source

Mineralocorticoid receptor knockout alters hippocampal CA2 neurons to become like those in CA1. [PDF]

Commun Biol
Harris EP, Kandemir B, Jones SM, Alexander GM, Ward JM, Wang T, Proaño S, Xu X, Dudek SM.   +8 more
europepmc   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]

Eur J Heart Fail
Kobayashi M, Duarte K, Ferreira JP, Baudry G, Monzo L, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F, Girerd N.   +9 more
europepmc   +1 more source

Prostaglandin D₂ Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone-Mineralocorticoid Receptor Pathway in the Heart. [PDF]

Cells
Garg A, Juchem M, Biss S, Borisch CN, Leonardy J, Bär C, Gupta SK, Thum T.   +7 more
europepmc   +1 more source

Clinical implications of mineralocorticoid receptor overactivation. [PDF]

Clin Kidney J
El Mouhayyar C, Chhikara M, Tang M, Nigwekar SU.   +3 more
europepmc   +1 more source

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Svanström H, Mkoma GF, Hviid A, Pasternak B.   +3 more
europepmc   +1 more source

Mineralocorticoid receptor antagonism for non-diabetic kidney disease. [PDF]

Nephrol Dial Transplant
Jaisser F, Barrera-Chimal J.
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Dibo P, Mareddy NSR, Kojima GSA, Ershed M, Obi OS, Razaq S, Kumar V.   +6 more
europepmc   +1 more source

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. [PDF]

JACC Adv
Alfarano M, Marchionni G, Costantino J, Ballatore F, Verardo R, Miraldi F, Ciciarello FL, Petramala L, Letizia C, Frustaci A, Chimenti C.   +10 more
europepmc   +1 more source